BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210126
DTEND;VALUE=DATE:20210129
DTSTAMP:20260515T150031
CREATED:20201027T084532Z
LAST-MODIFIED:20201027T084532Z
UID:27681-1611619200-1611878399@www.pharmajournalist.com
SUMMARY:TGFβ for Immuno-Oncology Drug Development Summit
DESCRIPTION:The world of TGFβ is at a tipping point within industry\, for an explosion of data to come.  \nExploring the wide array of approaches being utilized in pharma\, biotech\, and academia\, the TGFβ for Immuno-Oncology Drug Development Summit is the ONLY industry-led event dedicated exclusively to exploring TGF-beta’s role in cancer therapeutics. This 3-day summit is your definitive meeting to delve into the core challenges of this complex target.  \n \nDon’t miss out on your chance to deepen your understanding of cell signaling mechanisms\, change your view of the tumor microenvironment\, and prepare your candidates for the clinic to ensure patient safety.   \nJoin your peers this year to: \n\nHear from Scholar Rock on the selective inhibition of TGFβ1 activation with SRK-181\, their phase 1 candidate  \nDiscover the latest on Bintrafusp Alfa clinical trials from James Gulley at NCI\, and Clinical Development from Yan Lan at EMD Serono \n\n\nExplore the mechanism of action data from Novartis on their anti-transforming growth factor-beta antibody XOMA089 \nGet involved in Takeda\, Scholar Rock\, Oncotelic\, and Sanofi’s debate the best TGF-beta isoform to target\, combination vs monotherapy approaches\, and the winning therapeutic approach  \nContrast Small Molecule vs Antibody approaches to utilizing Integrin Inhibition with presentations from Morphic Therapeutic and Venn Therapeutics  \n\n To know more about TGFβ for Immuno-Oncology Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/tgf%ce%b2-for-immuno-oncology-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210126
DTEND;VALUE=DATE:20210129
DTSTAMP:20260515T150031
CREATED:20201204T104141Z
LAST-MODIFIED:20201204T104141Z
UID:28158-1611619200-1611878399@www.pharmajournalist.com
SUMMARY:4th Antigen Specific Immune Tolerance Summit (ASIT)
DESCRIPTION:The 4th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity\, allergy\, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen specific immunotherapies\, ASIT 2021 will be the only antigen-specific summit offering thought-leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development. \n \nThis is the industry’s definitive antigen specific drug development forum. \nAcross 3 packed days\, thought leaders from Novartis\, ImCyse\, Harvard Medical School\, Toleranzia\, Toralgen will reveal insight\, data\, and lessons learned from the last 12 months to enable you to hurdle the roadblocks preventing the development of clinically safe and effective antigen-specific immunotherapies for autoimmune and immune mediated disorders. \nTo know more about 4th Antigen Specific Immune Tolerance Summit (ASIT) please click here.
URL:https://www.pharmajournalist.com/event/4th-antigen-specific-immune-tolerance-summit-asit/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR